 | | Vol. 14.37 – 19 September, 2023 |
| |
|
|
| Investigators conducted a Phase II study, ALYCANTE, to assess the efficacy and safety of a single axi-cel infusion as a second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma deemed ineligible for autologous stem cell transplantation but eligible for CAR-T cell therapy.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers demonstrated that pharmacologic and genetic inhibition of neutral sphingomyelinase-2 led to sustained improvements in long-term competitive transplantation efficiency after ex vivo culture.
[Blood] |
|
|
|
| Using tractable mouse models for T cell non-Hodgkin lymphomas and primary patient samples, investigators demonstrated that PD-1 signaling suppressed T cell malignancy by restricting glycolytic energy and acetyl coenzyme A production.
[Nature Cancer] |
|
|
|
| Using CRISPR/Cas9 screening, researchers found that loss of ABCC1 strongly increased the sensitivity of AML cells to Venetoclax. Genetic and pharmacologic ABCC1 inactivation potentiated the anti-leukemic effects of BCL-2 inhibitors and efficiently re-sensitized Venetoclax-resistant leukemia cells.
[Nature Communications] |
|
|
|
| Using a transgenic mouse model, scientists demonstrated that truncated protein phosphatase magnesium-dependent 1 delta (PPM1D) reduced self-renewal of HSCs in basal conditions but promotes the development of aggressive AML after exposure to ionizing radiation.
[Leukemia] |
|
|
|
| Investigators described the development of CBFA2T3-GLIS2-driven mouse models of pediatric acute megakaryoblastic leukemia (AMKL) that recapitulated the phenotypic and transcriptional signatures of the human disease.
[Cell Reports] |
|
|
|
| Scientists generated a hematopoietic-specific conditional Samd14 knockout mouse model (Samd14-CKO) to study the role of Samd14 in hematopoiesis. The Samd14-CKO mouse was viable and exhibited no steady-state hematopoietic phenotype.
[Experimental Hematology] |
|
|
|
| To develop novel drugs for treating T-cell acute lymphoblastic leukemia (T-ALL) and AML, a series of analogs having a polyenylpyrrole structure of natural compounds were synthesized and investigated their structure–activity relationships of in vitro anti-T-ALL and anti-AML activities.
[Bioorganic & Medicinal Chemistry Letters] |
|
|
|
| | Scientists explored the efficacy of sorafenib therapy in this population with different concomitant genetic patterns. In a multi-center, cohort study, they enrolled patients with FLT3-ITD AML undergoing allogeneic hematopoietic cell transplantation.
[Signal Transduction And Targeted Therapy] |
|
|
|
|
| The authors review recent advancements in the field of clonal hematopoiesis and how it may affect the disease’s development in old age.
[Cell Death Discovery] |
|
|
|
| | Kymera Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T cell Lymphoma and relapsed/refractory (R/R) Peripheral T cell Lymphoma.
[Kymera Therapeutics, Inc.] |
|
|
|
|
| October 2 – 4, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | Cardiff University – Cardiff, Wales, United Kingdom |
|
|
|
| | Versiti Blood Research Institute – Wisconsin Rapids, Wisconsin, United States |
|
|
|
| | The Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| Center for Biologics Evaluation and Research – Silver Spring, Maryland, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
